Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.40M | 2.97M | 2.25M | 1.74M | 812.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.80M | 2.97M | 2.25M | 2.09M | 1.88M |
| Operating Income | -3.80M | -2.97M | -2.25M | -2.09M | -1.88M |
| Income Before Tax | -11.00M | -10.21M | -2.27M | -1.05M | -2.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.00 | -10.21 | -2.27 | -1.05 | -2.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.00M | -10.21M | -2.27M | -1.05M | -2.12M |
| EBIT | -3.80M | -2.97M | -2.25M | -2.09M | -1.88M |
| EBITDA | -3.80M | -2.70M | -1.82M | -1.12M | -- |
| EPS Basic | -0.40 | -0.38 | -0.09 | -0.06 | -0.12 |
| Normalized Basic EPS | -0.13 | -0.12 | -0.11 | -0.08 | -0.08 |
| EPS Diluted | -0.40 | -0.38 | -0.09 | -0.06 | -0.12 |
| Normalized Diluted EPS | -0.13 | -0.12 | -0.11 | -0.08 | -0.08 |
| Average Basic Shares Outstanding | 113.41M | 94.91M | 85.31M | 75.80M | 70.00M |
| Average Diluted Shares Outstanding | 113.41M | 94.91M | 85.31M | 75.80M | 70.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |